NEW YORK, July 18, 2018 /PRNewswire/ -- If you want a free Stock Review on HTGM, PKI, PRAH, and PRPO sign up now at https://stocktraderreport.com/registration/.On Tuesday, July 17, 2018, the NASDAQ Composite closed the trading session at 7,855.12, up 0.63%; the Dow Jones Industrial Average edged 0.22% higher, to finish at 25,119.89; and the S&P 500 closed at 2,809.55, slightly
HTG Molecular Diagnostics
USA-based HTG Molecular Diagnostics Inc.'s stock finished Tuesday's session 1.89% higher at $3.23 with a total trading volume of 167,745 shares. The Company's shares have advanced 17.45% over the past twelve months and 59.11% since the start of this year. The stock is trading below its 50-day moving average by 10.11%. Additionally, shares of the Company, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have a Relative Strength Index (RSI) of 42.26. Get the full research report on HTGM for free by clicking below at:https://stocktraderreport.com/registration/?symbol=HTGM
On Tuesday, shares in USA-headquartered PerkinElmer Inc. recorded a trading volume of 499,682 shares. The stock ended the session 1.15% higher at $76.37. The Company's shares have advanced 9.19% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.46% and 2.40%, respectively. Moreover, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 58.47 and have a dividend yield of 0.37%.
On July 16th, 2018, PerkinElmer announced that it will release its Q2 2018 results on August 01st, 2018, after market close. The Company will host a conference call that same day at 5:00 p.m. EDT to discuss these results. Robert Friel, Chairman and CEO, and Jamey Mock, Senior Vice President and CFO, will host the conference call. Get access to our top-rated research, including the free report on PKI at:https://stocktraderreport.com/registration/?symbol=PKI
PRA Health Sciences
USA-headquartered PRA Health Sciences Inc.'s shares closed the day 0.10% lower at $99.42. The stock recorded a trading volume of 423,637 shares. The Company's shares have gained 12.20% over the previous three months and 31.63% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 11.65% and 14.98%, respectively. Additionally, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 75.90.
On July 12th, 2018, PRA Health Sciences announced that it will release its Q2 results after the market closes on August 01st, 2018. The Company will host a conference call on August 02nd, 2018, at 9:00 a.m. ET to discuss the results with members of the investment community. A live audio broadcast will be available under the investor relations section of the Company's website. Click here to subscribe for a free membership which welcomes you with our report on PRAH at:
Shares in USA-based Precipio Inc. finished 8.86% higher at $0.37. The stock recorded a trading volume of 563,011 shares. The stock is trading below its 50-day moving average by 12.83%. Furthermore, shares of Precipio, which provides diagnostic products and services to the oncology market, have an RSI of 46.80.
On June 26th, 2018, Precipio announced an agreement with Israel-based artificial intelligence pathology platform company, Nucleai, which specializes in applying Machine Learning and Machine Vision algorithms to pathology domain. Nucleai's team has adapted artificial intelligence technology previously used for satellite image analysis to the detection of cancer using biopsy image analysis to distinguish between abnormal, potentially malignant cells and normal cells. To get free access to your research report on PRPO, sign up at:https://stocktraderreport.com/registration/?symbol=PRPO
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: 917-979-2038Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-technical-research-reports-on-medical-research-stocks----htg-molecular-diagnostics-perkinelmer-pra-health-sciences-and-precipio-300682810.html
SOURCE Stock Trader Report
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All